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Abstract
It has been documented that ischemia reperfusion injury (IRI) in the liver is 
associated with complement pathway activation. Thus, blocking complement 3 (C3) 
genes using a small hairpin RNA (shRNA) can potentially prevent liver IRI.
Gene silencing of C3 in vivo was achieved via the administration of shRNA 
prior to IRI. Liver IRI was evaluated using histopathology, serum alanine 
aminotransferase (ALT), and aspartate aminotransferase (AST). Neutrophil 
accumulation was determined by myeloperoxidase assay. Oxidative stress was 
assessed by malondialdehyde and reactive oxygen species levels.
In comparison with control mice treated with scrambled shRNA, the serum 
levels of ALT and AST were significantly reduced in mice treated with C3 shRNA. 
Additionally, neutrophil accumulation and lipid peroxidase-mediated tissue injury 
were decreased after shRNA treatment. Tissue histopathology showed an overall 
amelioration of injury in shRNA-treated mice. Therefore, the silencing of the C3 gene 
proved to be a potential therapy for preventing hepatic IRI.
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Ischemia-reperfusion injury (IRI) occurs when a tissue is temporarily 
deprived of blood due to factors in the blood vessels, followed by the restoration of 
the blood supply resulting in an intense inflammatory reaction. Reperfusion of 
ischemic tissue after a period of ischemia can actually be more damaging than the 
ischemia itself. IRI is a key event in clinical conditions such as stroke, myocardial 
infarction, trauma, shock and solid organ transplantation [1-6].
Ischemic injury occurs when blood supply to organ tissues is blocked. Since 
blood is responsible for the delivery of oxygen and nutrients to tissues, an insufficient 
amount of blood will result in a lack of nutrients and hypoxia (when a region of the 
body is deprived of adequate oxygen supply) or anoxia (a complete deprivation of 
oxygen supply): conditions that will eventually lead to tissue damage. The metabolic 
waste build-up produced from the lack of oxygen will cause further and more severe 
damage in the ischemic tissue. The length of time a tissue can tolerate anoxia can 
varies. However, all the ischemic tissue will eventually become necrotic. The heart 
and the brain are organs that are susceptible to the most rapid damage if ischemia 
should occur. Ischemic injury in these organs that last 3-4 minutes will result in 
irreversible necrosis.
As previously mentioned, aerobic metabolism is interrupted during ischemia 
causing an accumulation of metabolic waste. When reperfusion allows oxygen to be 
available again, the aerobic metabolism resumes and generates reactive oxygen 
species (ROS). These ROS will then cause oxidative cell damage including
oxidations on DNAs, proteins and lipids. Cell damage can stimulate the synthesis of 
inflammatory cytokines and increase the expression of adhesion molecules, all of 
which will cause neutrophils and macrophages to accumulate and attack the 
reperfused tissue. Experimental animal models and observations obtained from 
patients undergoing surgery have proven that oxidative stress and inflammatory 
response will further induce tissue injury after reperfusion. [7-10],
1.2 Liver IRI
Although the liver receives a dual blood supply from the hepatic arteries and 
the portal vein and has a glycogen storage system which supports the anaerobic 
metabolism, ischemic and hypoxic injury of this organ is still quite common. This is 
due to the fact that the liver is a highly aerobic organ, making it acutely sensitive to 
hypoxic injury. Liver IRI occurs during hepatic surgical resection, liver 
transplantation, trauma, and hemorrhagic shock, which can lead to local or systemic 
organ dysfunction. During liver transplantation, IRI can cause up to 10% of early 
organ failure and can lead to highly severe consequences such as acute or chronic 
rejection [11-13]. Furthermore, marginal livers are highly susceptible to IRI, which 
contributes to the shortage of donor organs available for transplantation. Therefore, 
preventing patients from IRI is likely to increase the success of the transplantation.
Warm hepatic IRI is a major consequence of hepatectomy, liver 
transplantation and hemorrhagic shock. The intense inflammation triggered by IRI 
can lead to liver dysfunction or failure. There are two distinct phases of liver injury 
after warm IRI [14]. The initial phase is mediated by activated Kupffer cells,
releasing ROS which directly injures hepatocytes, while in the secondary phase 
neutrophils enter the liver and augment the hepatocellular injury.
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1.2.1 Types of Liver ischemia
There are two types of liver ischemia: cold ischemia and warm ischemia. Cold 
ischemia occurs during the period of graft preservation at 1-4 °C prior to 
transplantation. The major targets of cold ischemia injury are the nonparenchymal 
cells, such as sinusoidal endothelial cells (SEC) and Kupffer cells, which are affected 
within 30-60 min of reperfusion. In contrast, the hepatocytes remain morphologically 
well preserved even after extended periods of cold preservation [15, 16]. The function 
of the graft following transplantation correlates with the degree of SEC injury.
A cold preservation solution was developed in the mid-1980s at the 
University of Wisconsin (UW) [17]. This solution contains a cocktail of substances 
including lactobionate, raffinose, phosphate buffer, glutathione, colloids, and other 
various ions which together decreases lethal reperfusion injury to SECs after longer 
periods of cold storage. It also increases the safety of organ preservation for up to 24 
hours. This remarkable solution has made a breakthrough in liver transplantation 
worldwide [18].
Warm ischemia is used to describe the ischemia of cells and tissues under 
normothermic conditions. It occurs during liver transplantation, various forms of 
shock, trauma, and liver surgery. In the case of a liver transplantation, warm ischemia 
occurs during implantation: from the time the organ is removed from ice until it is re-
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perfused with recipient blood. In the donor, warm ischemia may occur in the case of 
non-heart-beating donor (NHBD) organ retrievals [19].
The injuries resulting from warm ischemia are different from those of cold 
ischemia. The main feature of warm ischemia injury is an early (3-6 hr) and large- 
scale apoptosis of hepatocytes after reperfusion. Cold preservation can protect organs 
by suppressing metabolism, but it does not completely abolish metabolism. During 
the cold preservation, cellular energy stores are slowly exhausted, intracellular pH 
and calcium concentrations are increased, and lysosomal enzymes are activated. Since 
the energy-dependent sodium/potassium pumps are also inactivated in this process, 
sodium influx and cellular swelling will occur. During re-warming at the time of 
implantation, cellular metabolic demand is increased. However, there is still a lack of 
oxygen and nutrients, which will significantly worsen the hepatocellular structure and 
its function. A relatively short period of warm ischemia is therefore more harmful to 
cells than a longer period of cold ischemia [20]. The degree reperfusion injury is 
correlated with the duration of ischemia: such that ischemia is tolerated only for a 
period of approximately 1 hr in normal livers and 30 min in cirrhotic livers [21]. At 
present, there is no efficient clinical treatment to prevent hepatic warm IRI in liver 
transplantation.
1.2.2 Phases of warm IRI in liver
Dr. Jaeschke and his coworkers established that there are two distinct phases 
of warm IRI of the liver [22-26]. The initial phase (2-3 hr after reperfusion) is 
mediated by Kuppfer cell activation and the production of ROS, such as superoxide
6
anion (O2 ) and hydrogen peroxide (H2O2) which directly injure hepatocytes. 
Complement activation is also critical in the initial phase of IRI as depletion of 
complement with cobra venom factor reduces Kupffer cell-induced oxidant stress [25, 
27]. The severe injury that develops during the late phase (6-48 hr after reperfusion) 
is mediated by recruited neutrophils that accumulate in the post-ischemic liver. The 
activation of the Kupffer cells in the initial phase triggers a cascade of inflammatory 
mediators which lead to the adhesion of neutrophils to the hepatic vascular 
endothelium and subsequent transmigration into the hepatic parenchyma. The 
activated neutrophils release ROS, elastase, cathepsin G, heparanase, collagenase and 
hydrolytic enzymes which lead to an inflammatory disorder that causes direct damage 
to hepatocytes [28-30],
1.2.3 Mechanisms of warm liver IRI
Warm liver IRI is a complex pathophysiology with a number of contributing 
factors (Figl.l). Oxidative stress and an excessive inflammatory response are two key 
mechanisms of injury during reperfusion [20, 31]. In the initial period of reperfusion, 
reperfusion activates Kuppfer cells which can release ROS and pro inflammatory 
cytokines such as tumor necrosis factor-alpha (TNF-a) and interleukin 1 alpha (IL- 
la). Complement activation and CD4+ T cell activation cause a continuous activation 
of Kuppfer cells [27, 32, 33]. Pro inflammatory cytokines, activated complement 
factors, CXC chemokines and adhesion molecules are responsible for the 
accumulation of neutrophils and its activation. Neutrophils induce inflammatory
7
responses and also release ROS, which will damage hepatocytes in the later phases of 
reperfusion injury [34],
Figure 1.1 The Mechanism of warm liver IRI
There are two phases of warm liver IRI: initial phase and late phase. In the initial 
phase, Kupffer cells are activated and neutrophils are recruited by ROS and 
proinflammatory cytokines. In the late phase of reperfusion, an excessive 
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1.2.4 Cell types involve in warm liver IRI 
Kupffer Cells
Kupffer cells are specialized macrophages which reside in the lining of the 
hepatic sinusoids that form a part of the reticuloendothelial system (RES) of the liver. 
In the initial stages of reperfusion, the activated Kupffer cells change their 
morphology and protrude into the sinusoids, which causes blood flow within the 
sinusoidal lumen to be reduced [35]. After 2-6 hr of reperfusion, activated Kupffer 
cells release a large amount of pro inflammatory cytokines, reactive oxygen species, 
chemokines and other mediators, all of which promote neutrophil accumulation and 
oxidative stress. During the late phase of reperfusion, chemoattractants released from 
Kupffer cells, cause activation and infiltration of neutrophils that lead to hepatocyte 
injury.
Neutrophils
Neutrophils are the most abundant type of white blood cells in mammals and 
form an essential part of the innate immune system. They are one of the first 
inflammatory cells to migrate toward the site of inflammation. To migrate to the site 
of infection or inflammation, neutrophils undergo a process called chemotaxis. This is 
when cells direct their movements according to the level of certain chemicals in the 
environment. Neutrophils have receptors on their surface that detect chemical 
molecules such as interleukin-8 (IL-8), interferon gamma (IFN-y), complement 5a 
(C5a) and Leukotriene B4 which direct them through their path of migration.
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Neutrophils are involved in both phases of hepatic IR injury. Chemoattractant 
molecules produced from Kupffer cells cause hepatic neutrophil infiltration at the 
initial phase of reperfusion. Accumulation and adhesion of neutrophils results from 
the interaction of selectins and integrins expressed in the membrane of neutrophils 
and intercellular adhesion molecules (ICAM) expressed on the endothelial cells, 
respectively. Pro inflammatory cytokines TNF-a and IL-la stimulate ICAM-1 
expression in hepatic endothelial cells during hepatic IRI [36]. During liver 
transplantation, the increase in ICAM-1 expression leads to acute liver rejection [37]. 
Neutrophil accumulation causes sinusoidal endothelial cell injury and contributes to 
hepatic microvascular dysfunction after liver IRI. Activated neutrophils amplify IRI 
through the release of the same mediators as those of Kupffer cells, but the number of 
mediators is much greater. The ROS and proinflammatory cytokines lead to 
irreversible tissue damage in the liver. Depletion of neutrophils results in the 
prevention of hepatocellular injury [38, 39].
CD4+ T-Cells
The role of CD4+ T-cells in tissue inflammation and organ injury resulting 
from IRI has been well documented [40, 41]. CD4+ helper T-cells infiltrate into the 
liver within an hour after reperfusion and provide another signal for neutrophil 
infiltration. CD4+ cells can be subdivided into Thl and Th2 cells. Thl cells can 
secrete IFN-y, tumor necrosis factor-beta (TNF-ß) and Granulocyte-macrophage 
colony-stimulating factor (GM-CSF). Interferon-gamma (IFN-y) and TNF-ß are 
potent activators of Kupffer cells and promote TNF-a and IL-la proinflammatory
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cytokine release by Kupffer cells. IFN-y and GM-CSF may also directly act on 
neutrophils and enhance their ability to damage liver tissues [42], CD4+ T cells have 
been shown to aggravate microvascular and hepatocellular injury by activating the 
endothelium, and increasing platelet adherence and neutrophil migration [43]. 
Immunosuppressants such as FTY720 and Sirolimus have been shown to ameliorate 
hepatic IRI by preventing T cell infiltration [44-46]. CD4+ T depleted mice exhibit 
decreased neutrophil infiltration, liver enzyme release, and hepatocellular necrosis in 
a later stage after hepatic IR [32]. Recent studies have found that CD4+ T cells 
function in liver IRI without the requirement of de novo Antigen-specific activation 
and are dependent on the CD40L-CD40 pathway [33]. The costimulation pathway of 
CD40L-CD40 has been identified as a potential therapeutic target for preventing liver 
IRI [47, 48],
1.2.5 ROS and oxidative stress in the liver
ROS are one of the first elements formed in the initial phase of reperfusion 
injury [49]. ROS are chemically-reactive molecules containing oxygen. ROS include 
hydroxyl radicals, the superoxide anion, and hydrogen peroxide which all play 
important roles in cell signaling and homeostasis [50], The major cellular source of 
ROS is the mitochondrion. Under normal conditions, ROS are cleared from the cell 
by the activation of superoxide dismutase, catalase, glutathione peroxidase and other 
molecules. Under environmental stresses, ROS levels are dramatically increased, 
resulting in significant damages to cell structures. This situation is known as
oxidative stress.
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Kupffer cells are the main source of ROS during the initial phase of IRI in the 
liver. After liver IR, the peroxidation of lipids and the oxidant of protein frequently 
occur through forming peroxynitrite [51, 52]. Peroxynitrite is recognized as an 
important toxic intermediate in oxidative tissue injury. Proinflammatory cytokines, 
activated complement factors 3a and 5a (C3a and C5a, respectively), and chemokines 
are responsible for neutrophil recruitment and the subsequent neutrophil-induced 
oxidative stress during the later reperfusion phase. Complement factors cause the 
continuous stimulation of Kupffer cells and lead to prolonged oxidant stress [53]. 
Kupffer cell and neutrophil-induced oxidant stress is an important factor in vascular 
and parenchymal cell injury during reperfiision. The ROS from the Kupffer cells and 
neutrophils can directly kill hepatocytes. The mechanisms of oxidant stress induced 
cell killing includes the oxidation of pyridine nucleotides, the accumulation of 
calcium in the mitochondria and the formation of superoxides by the mitochondria, 
which ultimately lead to the formation of membrane permeable transition pores and 
the breakdown of mitochondrial membrane potential. In addition to the direct 
cytotoxic effects, ROS can promote reperfiision injury through the stimulation of 
redox-sensitive transcription factors such as the nuclear factor-kappaB (NF-kB) and 
the activator protein-1 (AP-1) in endothelial cells and hepatocytes [54], The 
administration of antioxidants, particularly in the initial stages of reperfiision, could 
significantly decreases the severity of IRI in transplanted livers [49].
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1.2.6 Cytokines in liver IRI
Pro inflammatory cytokines play an important role in both starting and 
maintaining the inflammatory response in liver IRI. Cytokine levels also modulate the 
severity of injury after reperfusion. In addition to reactive oxygen and proteases, 
Kupffer cells are the major source of cytokines during reperfusion. TNF-a and IL-la 
are generated during reperfusion [55, 56]. These cytokines have high 
proinflammatory activity which inducing interleukin-6 (IL-6) and interleukin 8 (IL-8) 
synthesis. IL-8 is a potent neutrophil chemotactic factor and activating factor, and 
correlates with neutrophil infiltration in an IR model [57]. Adhesion molecules, 
together with chemokines and complement factors, recruit neutrophils amplify 
ischemic injury by releasing additional ROS, TNF-a, and diverse proteases [58]. Both 
TNF-a and IL-la can upregulate macrophage 1 antigen (Mac-1) on neutrophils and 
recruit these cells into the liver vasculature. In addition, they are also potent inducers 
of hepatic CXC chemokine synthesis [59].
TNF-a
TNF-a is a cytokine produced by numerous cell types in response to 
inflammatory and immunomodulatory stimuli. The primary role of TNF-a is to 
regulate immune cells. TNF-a is able to induce apoptotic cell death and inflammation, 
inhibit tumorigenesis, and promote cell regeneration. Liver production of TNF-a does 
not occur during hepatic ischemia, but serum and hepatic levels of TNF-a are rapidly 
elevated after reperfusion. The secreted TNF-a has local hepatic and remote systemic 
organ effects, notably on the lung. In turn, TNF-a induces Kupffer cells to proliferate
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more TNF-a [60]. TNF-a enhances oxidative stress-induced injuries and induces 
apoptosis in hepatocytes. As a central mediator in the liver IRI, it is clear that TNF-a 
is responsible for increasing adhesion molecule P-selectin, intracellular adhesion 
molecule 1 (ICAM-1), and chemokine expression, which further promote neutrophil 
migration into the hepatic microvasculature [61, 62]. Blockade of TNF-a prevents the 
expression of adhesion molecules as well as the expression of CXC chemokines 
which can attenuate neutrophil accumulation and subsequent liver injury [63, 64].
IL-la
IL-la is produced by various types o f cells, including macrophages, dendritic 
cells (DC), T-cells, and B-cells. In liver IRI, IL-la is also released by activated 
Kupffer cells and promotes ROS formation. IL-la is released in response to TNF-a 
and also upregulates free radical production by neutrophils [65]. Unlike TNF-a, 
which is expressed rapidly after reperfusion, IL-la expression is delayed and does not 
affect the expression of TNF-a. IL-la plays an important role in the induction of 
CXC chemokines, macrophage inflammatory protein 2 (MIP-2) expressions, and 
activation of NF-xp. These effects augment neutrophil accumulation in the liver but 
do not significantly alter the extent of hepatocellular injury. IL-la plays an accessory 
role in inflammatory responses [66],
Interleukin 12 (IL-12)
IL-12 is an interleukin that is naturally produced by dendritic cells and 
macrophages in response to antigenic stimulation. It plays an important role in T cell
16
differentiation and stimulates the growth and function of T cells. It stimulates the 
production of interferon-gamma (IFN-y) and TNF-a from T cells, and reduces the IL- 
4 mediated suppression of IFN-y [67]. IL-12 plays a central role in the induction of 
hepatic ischemia-reperfusion injury by regulating the production of TNF-a and IFN-y 
[68, 69], Lentsch et al. showed that the hepatic expression of IL-12 is upregulated 
during the period of ischemia [22, 69]. Mice treated with a neutralizing antibody to 
IL-12 as well as IL-12 p40 deficient mice displayed a production of TNF-a and IFN-y 
that was greatly reduced. Furthermore, hepatic neutrophil accumulation and 
hepatocellular injury were also greatly reduced. Thus, it is concluded that IL-12 plays 
an important role in the liver inflammatory response to ischemia and reperfusion.
1.2.7 Adhesion molecules in liver IRI
During the initial phase of liver reperfusion injury, Kupffer cells are activated 
and release pro inflammatory cytokines (TNF-a and IL-la) to recruit neutrophils. For 
neutrophil accumulation at the site of inflammation, three classes of cellular adhesion 
molecules (CAM) on the surface of neutrophils and SECs are activated. They are 
se lectins, integrins and members of the immunoglobulin superfamily.
Selectins are lectin-domain glycoproteins expressed on endothelial cells, 
platelets, and neutrophils. Selectins mediate the initial capture of leukocytes, and 
support the rolling and transit adhesion on to the vascular endothelium, respectively. 
P-selectin plays a major role in the earliest phase of rolling and adherence of 
neutrophils in the hepatic microvasclulature after IRI. There are two peaks of P-
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selectin expression after liver IRI. One occurs at 20 minutes and another at 5 hours 
after reperfusion [70, 71]. The increased neutrophil-endothelium interaction 
mediated by se lectins enhances the other two CAM’s engagement. P-se lectin 
expression also plays an important role for the adhesion of platelets to the hepatic 
endothelium [72], The adherent platelets are known to augment neutrophil adhesion 
at the sites of inflammation [73]. P-selectin deficiency significantly reduce the 
severity of hepatic IRI [72, 74].
The (32 integrins on neutrophils (i.e., Mac-1) bind to immunoglobulin-like 
adhesion molecules on the endothelial cells, leading to firm adhesion of neutrophils 
on the endothelial surface. This may facilitate an increase in neutrophil extravasation 
and migration to the inflammatory site. Intercellular adhesion molecules 1, 2 and 3 
(ICAM-1, 2 and 3), vascular cell adhesion molecule (VCAM)-l, and platelet 
endothelial cell adhesion molecule (PECAM)-l are members of the immunoglobulin 
like family. There is a low expression of ICAM-1 on endothelium and Kupffer cells 
in normal liver. Pro inflammatory cytokines can significantly stimulate ICAM-1 
expression on endothelial cells, causing ICAM-1 -02 integrin interaction to promote 
firm adhesion of neutrophils to SECs. Blocking ICAM-1 with a specific antibody can 
efficiently prevent hepatic IRI [75, 76].
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1.2.8 Complement System
The complement system consists of about 30 soluble and membrane-bound 
proteins and has long been recognized as an important mediator of innate immune 
defense and inflammation [77]. Activation of the complement system is a critical 
event in IR of both clinical and experimental studies [27, 78, 79]. There are three 
biochemical pathways that activate the complement system, including the classical 
pathway, the alternative pathway, and the mannose-binding lectin (MBL) pathway 
[80-82] (Figure 1.2). These pathways depends are initiated by different molecules for 
their initiation. The classical pathway is typically initiated when complement lq 
(Clq) binds to the IgM or IgG antigen/antibody complex or when Clq binds directly 
to the surface of the pathogen [83]. The alternative pathway is triggered by 
spontaneous C3 hydrolysis to form C3a and C3b. C3b then binds to the pathogenic 
membrane surface. The MBL pathway is activated by MBL binding to mannose 
residues on the pathogen surface, which activates the MBL-associated proteases 1 and 
2 (MASP1 and MASP2). MASP1 and MASP2 can split C4 into C4a and C4b and C2 
into C2a and C2b. C4b and C2a then bind together to form C3-convertase, which 
leads to the subsequent activation of C3 [84, 85]. A common feature of all three 
pathways is that complement 3 (C3) convertase cleaves and activates the C3 protein, 
creating C3a and C3b and causing a cascade of further cleavage and activation. C3b 
joins with C3 convertase (C4b2a) to form C5 convertase which can be cleaved to 
produce C5a and C5b. C5b induces the activation of the terminal complement and the
formation of the membrane attack complex (MAC) which is the end product of the 
complement activation pathway [86].
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Hepatocytes are mainly responsible for the biosynthesis of 90% of plasma 
complement components and their soluble regulators. Proinflammatory cytokines 
such as IL-la, IL-6, TNF-a, and IFN-y can induce a significant increase in 
complement components [87-89]. Complement cascade can be rapidly activated in 
the early stage of IRI. Complement activation leads to the release of the small 
complement fragments C3a and C5a, also known as as anaphylatoxins because they 
can cause mast cell degranulation with the release of histamine and other mediators 
that increase vascular permeability [90]. C3a and C5a upregulate the Mac-1 receptor 
on neutrophils, cause neutrophil migration, and induce neutrophil adhesion within 
sinusoids to produce a local inflammatory response [91, 92], They can also stimulate 
oxidative metabolism to produce the ROS in Kupffer cells and neutrophils. MAC can 
directly cause cell injury and stimulate arachidonate metabolism resulting in the 
release of prostaglandin E2 from macrophages, leukotriene B4 from neutrophils, and 
interleukin-1 and ROS from human monocytes [93, 94]. Since C3 plays a central role 
in the complement system, blocking activation of the complement pathway has been 
shown to be effective in reducing the pathology of various organ-specific IRI [27, 95- 
98]. Therefore, suppression of C3 is a favorable strategy in turning off complement 
activation to prevent IRI [99].
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Figure 1.2 Complement activation Pathway
There are three pathways for complement activation: the classical pathway, the 
alternative pathway, and the lectin pathway. Each of these pathways is triggered by 
different molecules on the pathogen surface. All three pathways result in C3 
activation and merge at the level of C3 convertase, resulting in the formation of the 
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1.3 RNA interference
RNA interference (RNAi) is an RNA-dependent process that permits 
sequence-specific posttranscriptional gene silencing induced by double-stranded 
RNA (dsRNA). Fire and Mello first announced their discovery of RNAi after 
injecting dsRNA into the worm Caenorhabditis elegans resulting in the silencing of 
the gene that had a complementary sequence to that of the introduced dsRNA [100]. 
In brief, the mechanism of RNAi requires that dsRNA be cleaved into small 
interfering RNA (siRNA) by the RNase III enzyme Dicer. Next, the sense strand of 
siRNA is removed and the antisense strand, which is complementary to the target 
gene, is left behind to guide a protein complex called RNA induced silencing 
complex (RISC) as it identifies and silences the target mRNA (Figure 1.3). Since its 
discovery, RNAi offers enormous potential for using as a tool not only in biological 
research but also therapeutics by silencing genes of interest.
Chemically synthesized siRNA and short hairpin RNA (shRNA) cloned into 
vectors are both used to perform RNAi [101]. ShRNA contains a sense and antisense 
strand and a loop sequence between two strands. Due to the complementarity of the 
sense and antisense fragments in their sequences, such RNA molecules tend to form 
hairpin-shaped dsRNA by flipping back on the loop sequence. The U6 or HI 
promoter is used to ensure that the shRNA is constitutively expressed. Transcription 
of shRNA is initiated by polymerase III (pol III) promoter in the nucleus and then 
transported into the cytoplasm where the hairpin loop is cleaved by DICER resulting 
in a 21 base pair double stranded siRNA which then triggers RNAi [102-104].
Since it was first introduced by Fire and Mello, RNAi has shown promising 
results in both research and clinical therapy in the past decade. Elbashir et al. first 
used RNAi in mammalian cells [105] and Song et al. first reported that siRNA can 
be used therapeutically in whole animals [106], In 2010, Davis et al. first 
demonstrated that siRNA administered systemically to humans can produce specific 
gene inhibition [107]. These studies highlight the enormous potential of using RNAi 
as a powerful therapeutic tool.
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Figure 1.3 RNAi mechanism
DsRNA is cleaved into small interfering RNA (siRNA) by the RNase III enzyme 
Dicer. Next, the sense strand of siRNA is removed and the antisense strand, which 
complementary to the target gene, is left behind to guide a protein complex called 
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1.4 Rationale and significance
In our previous study, we successfully knocked down C3 gene through gene 
silencing, which is effective in the prevention of IR injuries in cardiac IRI [108] and 
renal IRI models [109-112]. However, gene silencing ofC3 to prevent liver IR injury 
has not yet been tested. Currently, there is no effective way to prevent warm liver IRI 
so the discovery of a therapeutic strategy would be highly significant clinically. 
Complement activation has been shown to be an early event in hepatic IRI. C3 is a 
central molecule involved in the three pathways for complement activation. In this 
study, I evaluated the therapeutic potential of C3 shRNA knockdown in the 
ameliorating liver IRI.
1.5 Hypothesis
Complement activation plays an important role in liver IRI. C3 is the central 
and critical plasma protein of the three pathways of complement activation. Thus, 
silencing the gene C3 with shRNA can alleviate liver IR  in mice.
1.6 Specific aims
A. To validate C3 gene expression and silencing in vitro and in vivo.
B. To establish partial hepatic IR  model.
C. To prevent hepatic IRI by silencing the C3 gene.
D. To find protective mechanisms of C3 shRNA in alleviation of Liver IR .
Chapter 2 Materials and Methods
2.1 C3 shRNA preparation
2.1.1 C3 shRNA design
Three sequences in C3 mRNA were selected for RNAi targeting. The 
oligonucleotides contained target-specific sequences for C3, including C3-1 [5’- 
GATCCCGTCTTTAGGAA GTCTTGCA CA GT7CAAGAGACTGTGCAA G A CTTCCT 
AAAGA TTTTTTCCAAA-3’(sense) and 5’-AGCTTTTGGAAAAAA 
TCTTTA GGAAGTCTTGCA CA GTCTCTT GAACTGTGCAAGA CTTCCTAAA G A 
CGG-3’ (antisense)];C3-2 [5’- GATCCCGTTGTTCATAACCAGGTAGG 
TT C A AG AG AC CTA CCTGGTTA TGAA CAA t t t TTT CC AAA-3 ’ (sense) and 5’- 
AGCTTTT GGAAAAAA TTG TTC A TAACCA GGTA GGTCTCTT GAA 
CCTACCTGGTTATGAACAACGG-3\antisense)]; C3-3 [5’-GATCCCG 
TTCAA CTCTTCTA TGGTCCA CTTCAAGAGAG TGGA CCA TA GAA GA GTTGAATT 
TTTTCCAAA-3’ (sense) and 5’-AGCTTTTGGAAAAAA 
TTCAA CTCTTCTA TGGTCCA CTCT CTT G AAG TGGA CCA TA GAAGAGTTGAA 
CGG-3’ (antisense)]; the sequence for scrambled shRNA [5’-GATCCC 
ACTA CCG TA G TC A TCGGAGTA TTG AT ATCCG TA CTCCGA TGA CTA CGGTA G TV 
TTTTT GGAAA-3 ’ (sense) and 5 ’ - AGCTTTTGGA A AAAA4 CTA CCG TAGTCA TC 
GGAGTACGGATATCAATACTCCGATGACTACGGTAGTGG-T (antisense)] were 
designed and synthesized by Invitrogen (Carlsbad, CA). The synthesized hairpin 
siRNA oligonucleotides were annealed by mixing lpg of each sense and antisense 
oligonucleotides with the DNA annealing solution and incubating at 90°C for 3 min
then cooling at 37°C for 1 hr. The annealed shRNA was then ready for ligation with 
plasmid vector.
2.1.2 Preparing the vector for ligation
The pRNAT U6.1/Neo siRNA expression vector (genescript, Piscataway, NJ) 
was digested with BamHI and Hindlll restriction enzymes (NEB, Ipswich, MA) for 
ligation. In brief, 10 pg of pRNATU6.1 vector was mixed with 10U of BamHI, 
Hindlll and cut Buffer B (Roche, Laval, QC) and then incubated at 37 °C for lhr The 
digested vector was extracted using a QIAquick gel extraction kit (Qiagen Canada, 
Toronto, ON). The digested vector was then loaded into a 0.8% agarose gel and 
allowed to run for lhr at 80V. The linearized DNA fragment was excised from the gel 
with a clean, sharp scalpel. The gel slice was weighed, and added according to 3 
volumes of buffer QG to 1 volume of gel (100mg~100pl). The mixture was then 
incubated at 50 °C for 10 min. One gel volume of isopropanol (Sigma-Aldrich 
Canada, Oakville, ON) was added and mixed. The mixture was placed into the 
QIAquick spin column and centrifuged. Buffer PE was used to wash the column and 
then Buffer EB was used for eluting the digested vector. The concentration of the 
digested vector was measured by a spectrophotometer (Biorad, Mississauga, Ontario).
2.1.3 C3 shRNA expression vector ligation
A C3-shRNA expression vector that expresses hairpin siRNA under the 
control of the mouse U6 promoter and cGFP gene was constructed by ligating the
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annealed DNA oligonucleotides into a pRNATU6.1 vector. (Figure 2.1) In brief, the 
annealed shRNA was inserted and the digested pRNATU6.1 vector was mixed at a 
molar ratio of 3:1. T4 DNA ligase (NEB) and ligation buffer were added to the 
mixture and incubates at 16 for 1 hr The ligated shRNA vector is now ready for the 
transformation into competent DH5a cells (Invitrogen, Carlsbad, CA).
Figure 2.1 C3-shRNA vector (pRNAT-U6.1/Neo)
This figure demonstrates the C3 shRNA expression vector. The annealed C3 hairpin 
siRNA oligonucleotides were inserted into the vector under the control of the mouse 
U6 promoter. Before ligation, the vector was digested with BamHI and Hindlll 
restriction enzymes. ShRNA transfection efficiency in vitro and delivery in vivo can 
be tracked by the GFP marker controlled by CMV. It also contains the antibiotic 
resistant genes for ampicillin and neomycin. Ampicillin allows for the selection of 
C3 shRNA vector clones after transformation on an ampicillin containing plate. 
Neomycin can be used to establish a stable transfection cell line in vitro.
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BamH I Sense Strand Loop Antisense strand Terminator Hind III
-----------11----------------------------------------1(---------- 1|---------------------------1|------1 I I
5’ GATCCCGTCTTTAGGAAGTCTTGCACAGTTCAAGAGACTGTGCAAGACTTCCTAAAGATTTTTTCCAAA
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2.1.4 C3 shRNA vector transformation and mini preparation
DH5a competent cells (50 pi) were thawed and mixed with ligated shRNA 
vector (lOng). The mixture was then put on ice for 10 min and put in a 42°C water 
bath for 30 seconds afterwards. After the heat shock, the mixture was put back on ice 
for 3 min. Two hundred microliters of LB medium (Sigma) was added to the mixture 
and then incubated in a shaker at 37°C for lhr. The 200pl transformation mixture was 
then spread on a pre-warmed ampicillin selective agar plate. The plate was incubated 
overnight at 37°C.
A single fresh clone was picked from the overnight culture plate and added 
into 5ml of LB medium. The E.coli cultures were then incubated in a shaker at 37°C 
overnight. The plasmid DNA was purified using a QIAprep spin miniprep kit 
(Qiagen). The overnight cultures of E.coli were harvested by centrifugation. Buffer
PI, P2, and P3 from the miniprep kit were added to the pellet and centrifuged again
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for the collection of the supernatant. The supernatant was transferred to a spin column 
centrifuge and washed by Buffer PE. The purified C3 plasmid shRNA vector was 
then eluted by Buffer EB and sent for a sequence test.
2.1.5 Large Scale plasmid preparation
The E. coli stock, which has the correct sequence targeting of the C3 gene, 
was added to 500ml of LB medium and cultured at 37°C in a shaker overnight. The 
bacteria were collected by centrifugation and solutions I, II, and III were added. The 
supernatant from the centrifugation was filtered with a Kimwipes and isopropanol
was added and centrifuged to collect the pellets. The pellets were then dissolved in 
4ml TE buffer, and 4.21g CsCl (Sigma) and 200pl ethidium bromide (Sigma) were 
added. The mixture was centrifuged at 55,000 rpm at 20°C overnight. The red 
plasmid DNA band was pulled out using a syringe with an 18-gauge needle. Ethidium 
bromide was then extracted using water-saturated isobutanol (Sigma). The plasmid 
DNA was precipitated on ice by adding ethanol and then centrifuged. The pellets 
were mixed with Rnase A (Fermentas, Burlington, ON) and purified using the 
phenol-chloroform (Bioshop, Burlington, ON) method. The concentration of the C3 
shRNA vector was measured by a spectrophotometer and was then ready for in vitro 
and in vivo use.
2,2 Cell culture and C3 gene silencing in vitro
Mouse melanoma cell line B16-F10 cell (ATCC, Manassas, VA) were 
cultures with Dulbecco's Modified Eagle's Medium. To validate gene silencing, B16- 
F10 cells were co-transfected with C3 cDNA (Invitrogen, Carlsbad, CA), C3 shRNA, 
or scrambled (nonsense) shRNA using lipofectamine 2000 (Invitrogen). The C3 
cDNA alone and non-transfected B16 cells were served as controls. The B16 cells 
were then plated into a 12 well plate (2xl05 of cells per well) and allowed to grow 
overnight to reach 70% confluence. The cells were then transfected with 0.5 pg of C3 
shRNA, 2pg of C3 shRNA, or scrambled shRNA in 500pl opti-MEM (Invitrogen) for 
4 hr. 500pl of 20% FBS complete medium was added and cells were incubated for 24 
hr. Subsequently, 1 ml of complete medium was added and cells were incubated for
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24 hr. RNA was extracted from the transfected cells using Trizol (Invitrogen) and 
prepared for subsequent analysis.
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2.3 Flow cytometry
The B16-F10 cells were transfected with C3 shRNA using lipofectamine 2000. 
At the different time point after transfection (4, 12, 24, and 48 hr after transfection), 
the cells were harvested to check the GFP expression using flow cytometry. After the 
B16-F10 cells were transfected with C3 shRNA vector in a 12 well plate, the cells 
were washed by PBS at different time points. Then 0.05%Trypsin-EDTA was added 
to the cells and incubated at 37°C for 3 minutes. Complete culture medium was 
added to neutralize the trypsin and then the cells were collected and centrifuged. The 
supernatant was discarded and the pellets of the cells were washed by a running 
buffer containing 2% FBS in PBS. After centrifugation, the pellets were resuspended 
in 300plof running buffer in preparation for analysis on a FACS caliber flow 
cytometer (Becton Dickinson, San Jose, CA)
2.4 Mice
Male BALB/c mice, 6-8 week old, were purchased from Charles River 
(Wilmington, MA). The mice were maintained under strict pathogen-free conditions 
at the Animal Care and Veterinary Service of the University of Western Ontario. All 




In vivo gene silencing was performed based on a previously reported 
“hydrodynamic” injection method. Forty-eight hours prior to the IRI experiment, 
5mg/kg C3 shRNA and scrambled shRNA were diluted in 2ml of Ringer’s solution 
and intravenously injected into the mice through the tail vein for 7-1 Os [113-115].
2.6 Liver IRI model
Experimental liver IRI model was performed as previously described [116]. 
BALB/c mice were anesthetized with ketamine (100mg/kg) and xylazine (20mg/kg) 
by intraperitoneal injection. Mice were placed on a heated pad to maintain warm body 
temperatures during the surgery. A midline laparotomy incision was performed to 
expose the liver. The left lateral and median lobes of the liver were rendered ischemia 
by completely clamping the hepatic artery and the portal vein using microaneurysm 
clamps. This experimental model resulted in 70% segmental hepatic ischemia. After 
clamp placement, the intestines where placed back into the abdominal cavity and 500 
pi of 10U/ml heparinized saline was administered directly into the peritoneal cavity. 
The incision area was covered with moistened gauze and the body temperatures of the 
mice were maintained at 37°C. After 60 min of ischemia the clamp was removed and 
the abdomen was closed. Blood and liver tissues were collected for experimentation 
6hr and 24hr after reperfusion as described below.
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2.7 Assessment of liver function
When certain types of cells are damaged, they may leak enzymes into the 
blood, where they can be measured as indicators of cell damage. Alanine 
aminotransferase (ALT) is produced mainly in the liver and small amounts of this 
enzyme are also found in the heart, muscle and kidney. It is significantly elevated in 
hepatitis patients and other forms of acute liver damage. Aspartate aminotransferase 
(AST), has a similar role, but is not as specific to the liver. It is also found in other 
tissues, like the heart, muscles, kidneys, brain and lungs. When liver damage occurs 
and is associated with hepatic necrosis, blood levels of ALT and AST are elevated 
even before the clinical signs and symptoms of the disease appear. Therefore, ALT 
and AST levels can be used for the assessment of liver function.
Blood samples were obtained from the inferior vena cava 6 hr and 24 hr after 
reperfusion. The levels of ALT and AST in the serum were measured by the Core 
Laboratory at the London Health Science Centre.
2.8 Histopathology and Immunohistochemistry Examination
2.8.1 Frozen section
The C3 shRNA vector was administered to animals at different concentrations, 
from l-7mg/kg. Forty-eight hours after the administration, the liver tissues were 
collected and fixed in 4% paraformaldehyde (Sigma) solution for 4-8 hr. Tissues were
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then dissected and mounted in a Tissue-Tek optimum cutting temperature embedding 
compound (Cedarlane, Burlington, ON), snap-frozen in liquid nitrogen, and stored in 
-80°C. Five micrometer thick tissue sections were cut using a cryostat. GFP 
expression was visualized using microscopy.
2.8.2 Liver histology
Six and twenty-four hours after reperfusion, liver tissues were collected and 
tissue slices were fixed in 10% formalin for 3 days at room temperature. Tissues were 
formalin-fixed embedded in paraffin, and 5pm thick sections were stained with 
hematoxylin and eosin (H&E). These sections were examined in a blinded fashion by 
a pathologist. The histological criteria for the assessment of liver damage after IRI 
followed a standardized scale [117], in which the following parameters were 
quantified: congestion, or vacuolization (0 None, 1 Minimal, 2 Mild, 3 Moderate, 4 
Severe), and necrosis (0 None, 1 Single-cell of focal necrosis, 2 area of necrosis 
<30%, 3 area of necrosis 30-60%, 4 area of necrosis >60%).
2.8.3 Immunohistochemistry
For the immunohistochemical staining of TNF-a and IL-la, liver tissue 
esctions were fixed in formaldehyde and subjected to heat mediated antigen retrieval 
in citrate buffer (pH 6.0). Samples were then blocked for 10 min at room temperature 
followed by incubation with a rabbit polyclonal to anti-TNF-a (Abeam, Cambridge, 
MA) and a goat IgG anti-IL-la (R&D systems, Minneapolis, MN) antibody at a
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1:200 dilution factor for 30 min. HRP-conjugated goat anti-rabbit (Abeam) and rabbit 
anti-goat antibody (Abeam) were used as a secondary antibody.
2.8.4 MPO staining
Myeloperoxidase (MPO) is a peroxidase enzyme which is most abundant in 
neutrophils. It is used for indexing neutrophil accumulation in the liver after IRI. 
Immunohistochemical staining of MPO was performed by deparaffinating and 
rehydrating paraffin sections, and subsequent incubation was performed in a ready-to- 
use peroxidase blocking solution (Dako, Carpinteria, CA) to inhibit endogenous 
peroxidase. To block nonspecific background staining, the sections were incubated in 
10% horse serum. The sections were then incubated with rabbit IgG anti­
myeloperoxidase antibody at a dilution factor of 1:100 (Lab Vision, Fremont, CA), 
followed by incubation in EnVision Rabbit-HRP (Dako). After incubating with the 
chromogenic substrate, the sections were counterstained with hematoxylin. The slides 
were examined under a light microscope (Olympus BX51; Olympus Corp., Tokyo, 
Japan) at a magnification of 400x.
2.9 MDA assay
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Lipid peroxidation is a well-established mechanism of cellular injury and is 
used as an indicator of oxidative stress in cells and tissues. Lipid peroxides are 
unstable and decompose to form a complex series of compounds of which the most 
abundant is malondialdehyde (MDA). Therefore, the measurement of MDA is widely 
used as an indicator of lipid peroxidation [118].
The MDA-586 assay is based on the reaction between N-methyl-2- 
phenylindole (Rl, NMPI) and MDA at 45°C to form a stable, intensely colored 
carbocyanine dye. The reaction is carried out in hydrochloric acid and Probucol to 
minimize other lipid peroxidation products from reacting with NMPI to make assay 
specific for the MDA detection.
The content of MDA in the homogenate was determined using BIOXYTECH 
MDA-586 kit (Oxis Research, Portland, OR), followed by a published protocol [119]. 
The liver tissues were rapidly excised 6hr after reperfusion and flushed with ice-cold
phosphate-buffered saline (PBS) via the portal vein before homogenization. 200-
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300mg of liver tissue was homogenized in 1ml of PBS containing 5mM of butylated 
hydroxytoluene. The samples were centrifuged at 14,000g for 10 min and 200pl of 
the supernatant was transferred to another eppendorf tube. Probucol and diluted N- 
methyl-2-phenylinedole were added to the homogenized liver tissue. After the 
addition of hydrochloric acid, the samples were incubated at 45°C for 60 min. The 
supernatants were obtained after centrifugation at 14,000 g for 10 min, and the 




2.10 ROS detection- DCF assay
The level of intracellular accumulation of ROS was determined by the T - T -  
dichlorofluorescein (DCF) assay. When 2’, 7’-dichlorofluorescein diacetate (DCFH- 
DA, Sigma) was applied to intact cells and crossed the cell membranes, it was 
hydrolyzed by intracellular esterases to nonfluorescent DCFH. In the presence of 
ROS, such as oxygen (O2)", hydrogen peroxide (H2O2), hydroxyl radical ( OH), and 
singlet oxygen ('02), DCFH was rapidly oxidized into highly fluorescent T - T -  
dichlorofluorescein (DCF). The increase in the fluorescence can be measured in a 
microplate reader at excitation and emission wavelengths of 485 and 525 nm, 
respectively. Thus, the DCF fluorescence can be used as an index to quantify the 
overall oxidant stress in cells [120-122].
DCFH-DA was dissolved in DMSO to a final concentration of lOpM before 
use. Liver tissues were homogenized in a cold Kreb’s buffer (table 2.1). After 
centrifugation to remove cell debris, the homogenate (200pg proteins) was incubated 
with lOpl of DCF-DA for 30 minutes at 37°C in a 96 well plate. The intensity of the 
fluorescence was recorded using a fluorescence spectrophotometer (Victor 3, Wallac). 
ROS levels were calculated as a ratio compared with control liver tissue samples.











2.11 Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from liver tissues and B16 cells using Trizol™ 
(Invitrogen) according the manufacturer’s protocol. In brief, 0.5ml of Trizol Reagent 
was added into 6xl05 B16 cells and 50mg of liver tissue (homogenized in the Trizol 
Reagent). One hundred microliter of chloroform was added to the mixture and 
centrifuged at 15,000rpm at 4°C for 15 min. The top aqueous phase was transferred to 
a new tube, and then isopropanol was added and incubated at room temperature for 
10 min. After centrifugation, the supernatant was discarded and the ethanol was 
added to wash the RNA pellet. After centrifugation, the ethanol was discarded and 
the pellet was dried at room temperature. RNase-free water (Invitrogen) was added to 
dissolve the RNA and the concentration was measured by a spectrophotometer.
Three microgram of total RNA was reverse-transcribed using an oligo-(dT) 
and reverse transcriptase (Invitrogen). The total RNA was mixed with oligo(dT), the 
mixture was heated at 70°C for 10 min, and was quickly chilled on ice for 5 min. 
RNase inhibitor, dNTP, and reverse transcriptase (NEB) were added, and then the 
mixture was incubated at 42°C for 50 min. The reaction was then inactivated at 70°C 
for 15 min. The cDNA is now ready for the PCR.
PCR was performed under the following conditions: DNA was initially 
denatured at 95°C for 3 min, followed by 30 cycles of denaturation at 95°C for 30 sec, 
annealing at 58°C for 30 sec, and then extension at 72°C for 30 sec. A final extension 




Real-time PCR reactions were performed in a Stratagene Mx3000P QPCR 
System (Agilent Technologies, Lexington, MA) using SYBR green PCR Master Mix 
(BioRad) and lOOnM of forward and reverse primers. The sequences were the same 
as those used in RT-PCR. The PCR reaction condition was 95°C for 10 min, 95°C for 
30 sec, 58°C for 45 sec, and 72°C for 30 sec (40 cycles). Relative quantification 
normalized to the GAPDH gene. The 2_AACt method for relative gene expression 
analysis is used [123].
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The data was expressed as a mean ±SD. Statistical comparisons among groups 
were performed using a one-way analysis of variance followed by the Newman-Keuls 
Test. Statistical significance was determined as /?<0.05.
Chapter 3 Results
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3,1 In vitro delivery of C3 shRNA vector
In order to validate the gene silencing efficacy of the shRNA vectors, I first 
determined if shRNA could effectively be transfected into the cells. To do this, I used 
an easily- transfected cell line, B16-F10. From 4 to 48hr after transfection, I checked 
GFP expression using a fluorescence microscope (Figure 3.1.1) and with flow 
cytometry (Figure 3.1.2). The microscope results were able to show that GFP was 
already expressed 4hr after transfection, but only in a low intensity. Furthermore, 
flow cytometry results revealed that around 30% of cells had a low GFP expression 
4hr after transfection (Figure 3.1.2), and that GFP expression was increased time 
extented. Forty-eight hours after transfection, 95% of the cells showed fluorescence 
of GFP (Figure 3.1.1 & 3.1.2). These results suggest that shRNA can be transfected 
into B16-F10 cells and that 48hr after transfection, the cells exhibited the highest GFP 
expression with the time frame tested. These results were able to help us concluding 




Figure 3.1.1 Time point of GFP expression after transfection
B16-F10 cells were transfected with 1 pg of C3 shRNA vector and 2pl of 
Lipofectamine 2000™ transfection reagent. From 4 to 48hr after transfection, the 
fluorescence of GFP was observed under a fluorescence microscope.
A) non-transfected cells
B) 4hr after transfection
C) 12hr after transfection
D) 24hr after transfection
E) 48hr after transfection






Figure 3.1.2 Flow cytometry analysis of GFP expression after transfection.
B16-F10 cells were transfected with lpg of C3 shRNA vector and 2ul of 
Lipofectamine 2000™ transfection reagent. From 4 to 48 hr after transfection, the 
cells were harvested and flow cytometry was run to analyze the fluorescence of GFP.
A) non-transfected cells,
B) 4hr after transfection
C) 12hr after transfection
D) 24hr after transfection,
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3.2 Silencing of C3 Gene in Vitro
B16-F10 cells were tested using RT-PCR. The results showed that B16 cells have a 
very low C3 gene expression. To determine the gene silencing efficacy of C3 shRNA 
vectors, we co-transfected C3 cDNA vectors together with C3 shRNA vectors into 
B16 cells. Transfection with C3 cDNA resulted in more than a 4-fold upregulation in 
the B16 cells. In order to assess the efficacy of gene silencing, cells were co­
transfected with C3 cDNA and specific shRNA. Forty-eight hours after co­
transfection, the silencing efficacy was determined through RT-PCR (Figure 3.2.A) 
and quantitative real time PCR (Figure3.2.B). C3 expression was markedly knocked 
down by the C3-1 shRNA vector when compared to the scrambled shRNA 
transfected B16 cells. Approximately 90% reduction in C3 gene expression was 
achieved in the C3-1 shRNA transfected cells. This data confirmed the success of our 
C3 shRNA silencing methodology and provided a reference sequence and dose of
assessment in the in vivo studies.
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Figure 3.2 C3 gene silencing in vitro.
B16-F10 cells were co-transfected with C3 cDNA vectors and C3-1, 2, 3 shRNA or 
scrambled shRNA using lipofectamine 2000. Non-transfected cells served as a 
negative control. Forty-eight hr after transfection, cells were harvested and total 
RNA was extracted. The transcripts of C3 and GAPDH were determined using RT- 
PCR (A) and quantitative real time PCR (B). (* p  < 0.05, cDNA +C3-1 shRNA vs. 





3.3 In vivo shRNA delivery and silencing
Previous research demonstrated that systemic administration, using the 
“hydrodynamic” injection method, can effectively deliver siRNA into liver tissues 
[124]. Therefore, we attempted to deliver C3 shRNA into the liver using the same 
method and investigated C3 shRNA in vivo delivery and silencing. Mice were treated 
intravenously with l-7mg/kg of C3 shRNA or scrambled shRNA. Forty-eight hours 
after treatment, liver tissues were harvested for frozen sections segmenting and the 
fluorescence was checked under a microscope (Figure 3.3.1). The results showed that 
compared with the lmg/kg shRNA vector treatment, the liver tissue of 5mg/kg 
shRNA treatment mice showed a stronger GFP expression. The shRNA vector 
treatment was then increased to 7mg/kg. However, there was no significant increase 
in GFP expression. This result concluded that a shRNA vector can be successfully 
delivered to the liver through hydrodynamic injection.
Next, we tested the gene silencing efficiency in vivo. Hepatocyte is the main 
area of C3 synthesis. To test gene C3 shRNA vector gene silencing, we extracted 
RNA from C3 shRNA or scrambled shRNA vector treated mice and performed Real 
time PCR (Figure 3.3.2). The results indicated that in contrast with the scrambled 
vector, the C3 shRNA vector could dramatically down regulate C3 gene expression in 
the liver.
The reduction of C3 gene expression is dose dependent. The dose of lmg/kg 
shRNA vector decrease C3 gene expression to around 20-30%. C3 shRNA vector 
dose at 2mg/kg can knock down C3 gene expression in vivo by 50%, and at 5mg/kg, 
the expression of C3 was decreased to around 90%. In comparison with the 5mg/kg
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dose, a 7mg/kg dose did not induce a greater reduction of C3 gene expression in vivo. 
Based on these results, the dose of 5mg/kg C3 shRNA was chosen for future studies.
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Figure 3.3.1 In vivo shRNA delivery
Mice were treated with l-7mg/kg C3 or scrambled shRNA vector by hydrodynamic 
injection through the tail vein. Forty-eight hours after treatment, liver tissues were 
collected and sectioned. The fluorescence of GFP was observed with a microscope.
A) lmg/kg shRNA vector
B) 2mg/kg shRNA vector
C) 5mg/kg shRNA vector
D) 7mg/kg shRNA vector






Figure 3.3.2 In vivo gene silencing of C3 gene
Mice were treated with l-7mg/kg C3 or scrambled (control non-targeting) shRNA 
vector by hydrodynamic injection through the tail vein. Forty-eight hours after 
treatment, liver tissues were collected and RNAs were extracted. Transcripts of C3 
and GAPDH were determined using quantitative real time PCR.
(* p  < 0.01, 5mg/kg or 7mg/kg C3 shRNA vs. scrambled shRNA, ** p < 0.05, 
lmg/kg or 2mg/kg C3 shRNA vs. scrambled shRNA, # jp>0.05, 5mg/kg C3 shRNA 
vs.7mg/kg C3 shRNA, ## p<0.5, 5mg/kg C3 shRNA vs. 2mg/kg C3 shRNA. n=6 per 
group)
&
Relative quantity mRNA level of C3 













3.4 Persistence of C3 shRNA silencing in vivo
To further test C3 shRNA vector gene silencing in vivo, we treated mice with 
5mg/kg C3 shRNA vector or scrambled shRNA vector by hydrodynamic injection 
through tail vein. Liver tissues were collected from day 1 to day 7 after treatment. 
RNAs of the liver tissues were extracted and quantitative real time PCR was 
performed (Figure 3.4). The results indicated that 24 hr after treatment with the C3 
shRNA vector down regulated C3 gene expression in the liver by 50%, scrambled 
shRNA could not decrease but rather stimulated C3 gene expression by 10-15% in the 
liver. Forty-eight hours after treatment, C3 shRNA decreased C3 gene expression by 
80%. Seventy-two hours after treatment the gene silencing efficiency was similar to 
that of 48 hr. From day 4 to 7 after shRNA injection, the gene silencing efficiency 
decreased to 50%. The results suggested that the efficacy of gene silencing of C3 
gene lasted at least 7 days after administration of shRNA, which is sufficient to 
protect from IRI most commonly occurring at first 48hr in transplantation. Forty-eight 
hours after treating mice with C3 shRNA showed the best effects. Thus, pretreating 
with C3 shRNA was injected 48hr before inducing IRI was used for the following 
study.
3.5 C3 shRNA prevented C3 gene up-regulation induced by liver IRI
Mice were treated intravenously with 5mg/kg of C3 shRNA or the scrambled 
shRNA 48 hr before IRI induction. PBS treated sham-operated (unclamping of 
hepatic artery and portal vein to induce IRI) mice served as control. The level of C3
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gene expression in IRI livers was detected by real-time PCR (Figure 3.5). The results 
showed that the expression of C3 was significantly increased by IRI. Remarkably, C3 
expression induced by IRI in the liver was suppressed in mice pre-treated with C3 
shRNA.
3.6 C3 shRNA prevented hepatic dysfunction in IRI
We hypothesized that C3 shRNA could also prevent hepatic damage caused 
by complement activation in IR injury. In order to assess the degree of hepatic 
dysfunction exhibited by C3 shRNA-treated versus scrambled shRNA-treated mice, 
we measured levels of ALT and AST in sera that were collected from the IRI mice. 
Six hours after reperfusion, the levels of AST (Figure 3.6.A) and ALT (Figure 3.6.B) 
significantly increased in comparison with those of the unclamped sham controls. 
However, in contrast with the scrambled shRNA control, the serum levels of ALT 
(13296.5 ±1178.81U/L vs. 5326.14 ±853.16 U/L p<0.05) and AST (7965.80 
±1245.70U/L vs. 2532.40 ± 472.05U/L p<0.05) were significantly reduced in mice 
pre-treated with C3 shRNA. Twenty-four hours after reperfusion, the serum level of 
ALT and AST in C3 shRNA-treated mice remained at low levels, which were 
significantly low in comparison with those of the scrambled shRNA-treated mice. 
These results suggest that C3 shRNA protected liver from IRI.
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Figure 3.4 Persistence of C3 shRNA silencing in vivo
Mice were treated with the 5mg/kg C3 shRNA vector or the scrambled shRNA vector 
by hydrodynamic injection through the tail vein. From day 1 to day 7 after treatment, 
liver tissues were collected and RNAs from these liver tissues was extracted. 
Transcripts of C3 and GAPDH were determined using quantitative Real time PCR 
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Figure 3.5 C3 shRNA decreased C3 gene up-regulation induced by liver ERI
C3 shRNA or scrambled shRNA at the dose of 5mg/kg diluted in a volume of 2 ml 
were administered to mice through i.v. injections as described in Material and 
Methods. Forty-eight hours after injection, liver hepatic arteries and portal veins 
were clamped for 60 min to induce IRI. PBS treated sham-operated (unclamping of 
hepatic artery and portal vein to induce IRI) mice served as sham controls. Six hours 
after reperfusion, liver tissues were harvested and total RNAs were extracted. 
Transcripts of C3 and GAPDH were determined by quantitative real time PCR. (* p < 
0.01, C3 shRNA treated group vs. scrambled shRNA treated group, n=6 per group).
Relative quantity mRNA level of C3
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Figure 3.6 C3 shRNA reduced the effect of liver ischemia and reperfusion on 
liver function.
Serum samples were extracted after 60 min of ischemia and 6 or 24hr of reperftision. 
Sera was collected from sham control mice and mice with IRI treated with C3 shRNA 
or scrambled shRNA. Serum levels of ALT (A) and AST (B) were detected as 
described in Methods and Materials. The data shown is the mean ± SD (* p < 0.05; 
C3 shRNA treated group vs. scrambled shRNA treated group, n=6 per group).
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3.7 Histological changes in IRI after silencing C3 genes
To confirm the effects of shRNA, we further examined histopathological 
changes in the IRI livers. We collected liver tissues 6 hr and 24 hr after reperfusion. 
The histological score was based on the degree of congestion, vacuolization, and the 
area of hepatic necrosis (Table 3.1). Six hours after reperfusion, the livers from mice 
treated with scrambled shRNA were induced with profound IRI. Severe tissue 
damage was observed in the IRI liver, such as congestion, vacuolization, and necrosis 
(Figure 3.7). In contrast, mice pre-treated with C3 shRNA showed a significant 
attenuation of all pathological changes examined by 67-75% (Table 3.1).
3.8 C3 shRNA decreased the neutrophils infiltration in the IRI liver
Neutrophil accumulation is an important factor in liver IRI [117, 125]. MPO is 
a peroxidase enzyme most abundantly present in neutrophil granules.. To assess 
complement activation in hepatic IR injury on neutrophil accumulation, liver tissue 
samples were stained with an antibody against MPO. There was no appreciable 
neutrophil infiltration in the liver tissues of the sham-operated mice. However, in the 
scrambled shRNA treated group, a considerable number of neutrophils were 
identified in the livers at both 6 and 24hr after reperfusion. There was a higher 
neutrophil infiltration at 24hr than at 6hr after IRI in the scrambled shRNA treated 
mice. The livers of mice treated with C3 shRNA had a significantly decreased 
neutrophil accumulation at 6 and 24 hr after reperfusion. (Figure 3.8)
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Table 3.1 Histopathological score of IRI
Groups Congestion Vacuolization Necrosis
Sham 0.14±0.09 0.07±0.07 0.00±0.00
Scrambled shRNA 2.57±0.17 2.29±0.15 2.67±0.17
C3 shRNA 0.86±0.14 * 0.57±0.20 * 0.70±0.12 *
Liver IRI was induced by clamping the hepatic artery and portal vein for 60 min. Six 
hours after IRI, liver tissues were harvested and stained with H&E. The 
histopathological change was scored as indicated in Materials and Methods. The 
data shown is the mean± SEM. (*p<0.05 C3 shRNA group vs. scrambled shRNA 
group, n=6 per group).
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Figure3.7 Hepatic histopathology
BALB/c mice were pretreated with PBS (A) scrambled shRNA (B) or C3 shRNA 
(C). IRI was induced as described in Figure 3.5. Liver tissues were harvested 6hr 
after reperfusion and stained with H&E.
Magnification: 200x
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Figure3.8 Liver tissues stained with MPO
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were 
induced with IRI as described in Figure 3.7. At 6hr and 24hr after reperfusion, liver 
















3.9 C3 shRNA reduced hepatic IRI induced pro-inflammatory cytokine release
Proinflammatory cytokines such as TNF-a and IL-la [56, 60, 66] are 
generated mainly by Kupffer cells. Complement activation in IRI can stimulate 
Kupffer cells to release TNF-a and IL-la, aggravating hepatic injury. Through real 
time PCR (Figure 3.9.1) and immunohistochemistry (Figure 3.9.2), mice treated with 
C3 shRNA were shown to exhibit notably reduced levels of TNF-a and IL-la in liver 
tissues in comparison with scrambled shRNA treated mice observed 6hr after 
reperfiision injury.
3.10 C3 shRNA reduced IRI induced adhesion molecules expression
When Kupffer cells are activated, they release proinflammatory cytokines. 
TNF-a is responsible for increasing the adhesion molecule P-selectin, ICAM-1, and 
chemokine expression which further promote neutrophil accumulation in the liver
[126]. We proved that treating mice with C3 shRNA can significantly decrease TNF- 
a and IL-la level in liver tissues (Figure 3.9.1 and 3.9.2). Therefore, we tested 
adhesion molecule P-seletin and ICAM-1 expression in liver tissues 6 hr after the 
reperfusion injury (Figure 3.10). The quantitative real time PCR results showed that 
treating mice with C3 shRNA significantly decreased the expression of ICAM-1 and
P-selectin.
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Figure 3.9.1 TNF-a and IL -la  levels detected by real-time PCR
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were 
induced with IRI as described in Figure 3.5. A & B: TNF-a and IL-la level in liver 
tissue detected by real-time PCR. Transcripts of TNF-a (A) and IL-la (B) were 
determined by quantitative real time PCR. The data shown is the mean ± SEM (*p <





Figure 3.9.2 Immunohistochemistry staining for TNF-a and IL -la
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were 
induced with IRI as described in Figure 3.5. TNF-a and IL-la level in liver tissues 
were detected by immunohistochemistry. Paraffin sections were stained with an 





Sham Scrambled shRNA C3 shRNA
81
Figure 3.10 C3 shRNA reduced IRI induced adhesion molecules expression
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were 
induced with IRI as described in Figure 3.5. A & B: ICAM-1 and P-selectin levels in 
liver tissues were detected by real-time PCR. Transcripts of ICAM-1 (A) and P- 
selectin (B) were determined by quantitative real time PCR. The data shown is the 
mean± SEM (*p < 0.05, C3 shRNA treated group vs. scrambled shRNA treated group, 
n=6 per group)
Relative quantity mRNA level of P-selectin
O  to  CO ^




3.11 C3 shRNA decreased malondialdehyde level in IRI liver tissue.
Lipid peroxidation is a well-established mechanism of cellular injury that is 
used to indicate oxidative stress in cells and tissues [127]. The measuring of 
malondialdehyde (MDA) levels is widely used as an indicator of lipid peroxidation in 
testing levels of oxidative damage. The initial phase of hepatic IR injury involves 
Kupffer cell activation and induced oxidative stress. Complement activation can 
activate Kupffer cells in hepatic ischemia reperfusion injury. In this study, we 
pretreated mice with C3 shRNA prior to inducing IR injury and found that compared 
with scrambled shRNA treated mice, C3 shRNA treated mice exhibited a significant 
depression of MDA levels. (Figure 3.11)
3.12 C3 shRNA reduced ROS in IRI liver tissue
Kupffer cell activation can release ROS after liver IRI. Complement 
activation can further activate Kupffer cells to generate more ROS. To test the 
oxidative stress injury in liver tissues, we also examined the ROS production in liver 
tissues using DCF assay [122] (Figure 3.12). The ROS production was significantly 
decreased in the mice treated with C3 shRNA in comparison with those treated with 
the scrambled shRNA vector group. This result along with those obtained from the 
MDA experiment, suggest that C3 shRNA treatment can significantly decrease the 
oxidative injury after reperfusion injury in liver tissues.
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Figure 3.11 C3 shRNA decreased oxidative injury in IRI liver.
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were 
induced with IRI as described in Figure 3.5. Six hours after reperfusion, liver tissues 
were harvested and the MDA content was determined using a MDA 586 kit, as 
described in Materials and Methods. The data shown is the mean ± SEM (*.P<0.05 





Figure 3.12 ROS production in liver tissue
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were 
induced with IRI as described in Figure 3.5. Six hours after reperfusion, liver tissues 
were harvested. The ROS production of liver tissues was measured a DCF assay as 
described in Material and Methods. The data shown is the mean ± SEM (*P<0.05 








C hapter 4 Discussions
Liver IRI during transplantation or liver surgery is still a major concern that 
can ultimately lead to organ dysfunction and/or failure. There are two distinct phases 
of liver IRI: the initial phase, which occurs in less than 2 hr of reperfusion, and the 
late phase, which occurs at 6-48h after reperfusion[14], The initial phase involves 
Kupffer cell activation, ROS production, and oxidative stress, which all eventually 
lead to the damaging of hepatocytes. In the late phase, which is associated with 
neutrophil infiltration, [39, 117, 128], the recruited neutrophils directly damage the 
hepatocytes by releasing oxidants and proteases [22].
The pathogenic mechanisms involved in IRI are complex and multifaceted but 
clinical and experimental studies in several organ systems, including that of the liver, 
have revealed that complement activation plays a major role in IRI [129-133]. 
Ischemia and reperfusion is a potent inducer of complement activation. Activated 
complement and inflammatory cells are involved individually and collaboratively in 
the formation of IRI. Complement is a complex cascade of 30 soluble and membrane 
bound proteins that are activated in an orderly manner by 3 different pathways. These 
three pathways are known as the classical, alternative, and MBL pathways. All 3 
pathways merge at the level of the complement component C3 and culminate in a 
common terminal pathway to generate chemotactic factors such as C3a and C5a and a 
terminating complex called the MAC (C5b-9). It seems that the specific contribution 
of the three pathways vary depending on the pathophysiologic mechanism in IRI of 
different organs. Several studies demonstrated that the classical or lectin pathway is 
involved in myocardial, gastrointestinal and, hind limb IRI [134-138]. The alternative
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pathway may contribute to kidney IRI [139] and the classical pathway is involved in 
liver IRI [140],
In humans, complement activation leading to the deposition of MAC is 
common during liver transplantation and contributes to cell injury and neutrophils 
infiltration to the allograft [141]. The MAC incorporated into the cellular membrane 
can activate endothelial NF-kB and increase the number adhesion molecules such as 
ICAM-1, VCAM-1 and P-selectins expression [142, 143]. The MAC can also 
stimulate endothelium to produce IL-8 and monocyte chemo attractant protein-1 
[144]. Furthermore, it can activate platelets and contribute to platelet-leukocyte 
aggregation [145].
C3a and C5a, generated from complement activation, participate in neutrophil 
accumulation. C5a can cause the increase of P-selectin and ICAM-1 expression, 
which mediate neutrophils and endothelial cells to form a firm adhesion. C5a, as a 
more potent inflammatory mediator, can also release pro inflammatory cytokines such 
as TNF-a and IL-la. As a strong chemo attractant, C5a can also recruit neutrophils to 
the injury site. The accumulation of neutrophils augments the injury of reperiusion. 
Since complement activation plays a key role in inducing IRI, it can be hypothesized 
that IRI can be attenuated through the use of complement inhibitors.
The contribution of complement in IRI has been well demonstrated in 
complement deficient models. Attenuated injuries were observed in the intestinal and 
hind limb IRI models of C3‘/_ and C4'/_ mice [134, 146, 147]. Another study showed 
that the mice in which C3 was deficient exhibited a protective effect in a renal IRI 
model [148]. In terms of therapeutics in preventing liver IR injury, block complement
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pathways using a C3 convertase inhibitor [33, 149], C5aR antagonist [150], and Cl 
inhibitor [98, 140, 151] have been effective in ameliorating liver IRI in rodent models. 
C3 was selected as a target for gene silencing in this study because it is the critical 
plasma protein of the complement pathway. It was predicted that its inhibition would 
effectively terminate the activation of the downstream complement cascade.
RNAi is a natural mechanism by which siRNA mediates the sequence specific 
cleavage of targeted RNA molecules. Therefore, RNAi is a powerful tool for the 
target specific knockdown of gene expression. Ever since this method of using RNAi 
was named the “ breakthrough of the year” in 2002 [152], there have been numerous 
studies using this novel technology which have provided results that could eventually 
be used for therapeutic applications. The therapeutic advantages of siRNA for 
treatment of viral infections, cancer, and neurological disorders show a great promise 
[153-155]. In comparison with antibodies, the prospects for siRNA are better because 
it is easily applicable to any therapeutic target including intracellular factors and even 
transcription factors. Also, gene silencing with siRNA is more powerful and exhibits 
exquisite selectivity. Amongst its other advantages, siRNA also has a low toxicity and 
provides easy screening for inhibition efficiency.
For siRNA delivery in vivo, previous studies have demonstrated that the liver 
is the primary site of siRNA uptake after hydrodynamic injection [113]. Song et al 
used Fas siRNA, which holds a therapeutic promise to prevent liver injury by 
protecting hepatocytes from cytotoxicity [106]. Another study showed that by treating 
mice with caspase 8 siRNA through hydrodynamic injection can prevent acute liver
failure [156]. Therefore, delivering siRNA to the liver by means of hydrodynamic 
injection is a proven and promising strategy for liver disease.
Naked non-chemical modification siRNA is relatively unstable in the blood 
and is rapidly cleared from the body via degradation by ribonucleases, rapid renal 
excretion, and nonspecific uptake by the reticuloendothelial system. Compared with 
siRNA, the shRNA vector is more stable and has a longer duration of silencing 
efficiency. RNAi using shRNA is a potent strategy in knocking down genes in vivo
[101]. We have previously demonstrated that the treatment of shRNA that are specific 
to complement genes had a promising therapeutic potential in preventing heart [108] 
and renal IR1 [109-112]. In this study, we were able to prove that gene silencing of 
C3 using shRNA is effective in ameliorating liver IRI (Figure 3.6).
The liver (mainly hepatocytes) is responsible for the biosynthesis of 90% of 
injection is an efficient method for delivering shRNA plasmids to hepatocytes [113- 
115, 124], In this study, we demonstrated that successfully delivering and silencing 
C3 using a shRNA plasmid in the liver resulted in the prevention of liver IRI (figure 
3.5, 3.6).
The early phase of liver IR injury activates Kupffer cells which produce 
harmful levels of ROS. The release of ROS directly damages liver tissues in IR 
injury, moreover, ROS also stimulates Kupffer cells to produce pro-inflammatory 
cytokines such as TNF-a and IL-la [158]. TNF-a is produced by many cell types, 
including Kupffer cells, in response to various inflammatory and immunomodulatory 
stimuli in liver IRI. In this study, we detected elevated levels of TNF-a in the liver IRI 
mice, similarly shown in rat liver IRI models, in which TNF-a increased almost five
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folds compared with sham operated controls [159]. The proposed mechanisms by 
which TNF-a leads to liver IRI mainly do not include the mediation of direct toxicity 
to the mitochondria or inducing apoptotic or necrotic cell death.[l 59-161]. The 
increasing of IL-la was also observed in this study, showing that it may be stimulated 
by the inflammatory environment of liver IR or from its response to the upregulation 
of TNF-a. Interestingly, a feedback loop between ROS and inflammatory cytokines 
may exist. While ROS stimulates TNF-a/IL-la to be released, TNF-a/IL-la also 
promotes neutrophils to produce ROS. In the late phase, IL-la may activate the 
infiltrated neutrophils in liver IRI, which will result in the production ROS [128], 
Turning off this feedback loop is seemingly impossible unless all pathways involved 
are efficiently blocked. In this study, the knockdown of the C3 pathway significantly 
attenuated the production of both ROS and inflammatory cytokines. Our results 
showed that by silencing C3 gene expression in IRI, the liver will down-regulate its 
levels TNF-a, IL-la and decrease the generation of ROS (Figure 3.9.1, 3.9.2, 3.12).
Neutrophils are involved in both phases of hepatic IRI. Kupffer cell activation 
and the release of pro-inflammatory cytokines, such as TNF-a and IL-la, can activate 
the systemic neutrophil function and lead to the accumulation and adherence of 
neutrophils to hepatocytes, inducing hepatocyte necrosis. With complement factors 
and platelet activating factor, TNF-a and IL-la can induce neutrophil accumulation in 
the liver. Furthermore, TNF-a and complement factors can upregulate CXC 
chemokines and adhesion molecule expression to augment neutrophil accumulation 
and induce neutrophil-mediated injury after reperfusion. Blocking the complement 
pathway using C3 shRNA can significantly decrease pro-inflammatory cytokine
levels and adhesion molecules P-selectin and ICAM-1 expression, promoting a 
decrease of neutrophil infiltration in liver tissues.
Lipid peroxidation refers to the oxidative degradation of lipids and is used as 
an indicator of oxidative stress in cells and tissues. Lipid peroxides are unstable and 
decompose to form a complex series of compounds, of which the most abundant is 
MDA. Our results indicated that by knocking down C3 gene expression in the liver, 
IRI can be alleviated hepatic MDA levels (Figure 3.11).
In conclusion, our studies have demonstrated that the systemic administration 
of C3 shRNA resulted in the silencing of C3 expression, prevented IRI, suppressed 
inflammatory cytokine production, and withheld neutrophil infiltration in the liver. 
The use of C3 shRNA may eventually represent a novel approach in preventing 
complement mediated liver damage and become an efficient aid in liver 
transplantations and other conditions associated with liver IRI.
Future study
Effective in vivo delivery of siRNAs to specific target organs or cells is the 
most important challenge in respect of clinical applications. In this study, we 
demonstrated that treating mice with a C3 shRNA vector by means of hydrodynamic 
injection through the tail vein successfully delivered shRNA to the liver, knocked 
down C3 gene expression, and prevented liver IRI in a murine model. But this high 
volume, high pressure intravenous injection of siRNA or shRNA is not practical in 
clinical interventions. The ability to selectively deliver siRNA to specific cells would
allow for lower concentrations of siRNA to be used, as well as possibly alleviating 
the need for systemic delivery.
Cationic liposomes or nanoparticles have been used for siRNA in vivo 
delivery. Among these approaches, the most efficient systemic administration was 
achieved using stable nucleic acid lipid particles. Receptor-mediated liposomes may 
be able to provide an efficient method for siRNA systemic delivery. 
Asialoglycoprotein is expressed on the surface of the hepatocyte. Galactose 
specifically binds to the asialoglcorprotein receptor. In order to achieve hepatocyte- 
targeted delivery of siRNA, conjugating galactose to the liposome is hypothesized to 
provide a novel method of specifically delivering siRNA to the liver. The lipid-based 
liposome in combination with specific ligands for cell-target delivery of siRNA may 
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e.c. Approved Protocol 
Approval Letter
-  W . Min, X. Zhang, W . Lagerwert
-  W . Min, X. Zhang. W . Lagerwerf
The University o/W estern Ontario 
Animal Use Subcommittee / University Council on Animal Care 
Health Sciences Centre, •  London, Ontario •  CANADA -  N6A 5C1 
PH: 519-661-2 I I I ext. 66770 •  FL519-661-2028 •  www.mvo.ca/ammal
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